The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
Open accessAbstract
BACKGROUND: A recent epidemiological study suggested that 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials. OBJECTIVES: We examined self-reported improvement in depression and anxiety among people who use 5-MeO-DMT in a group setting with structured procedures guiding dose and administration of 5-MeO-DMT. Such procedures also include activities for the preparation of, and support during/following sessions, which are similar to procedures used in clinical trials of hallucinogen administration. Next, we examined whether depression or anxiety were improved following use, and whether the acute subjective effects (mystical/challenging) or beliefs about the 5-MeO-DMT experience were associated with improvements in these conditions. METHODS: = 47.7; Male = 55%; White/Caucasian = 84%) completed an anonymous web-based survey. RESULTS: Of those reporting having been diagnosed with depression (41%) or anxiety (48%), most reported these conditions were improved (depression = 80%; anxiety = 79%) following 5-MeO-DMT use, and fewer reported they were unchanged (depression = 17%; anxiety = 19%) or worsened (depression = 3%; anxiety = 2%). Improvement in depression/anxiety conditions were associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning of the 5-MeO-DMT experience. There were no associations between depression or anxiety improvement and the intensity of acute challenging physical/psychological effects during the 5-MeO-DMT experience. CONCLUSIONS: Future prospective controlled clinical pharmacology studies should examine the safety and efficacy of 5-MeO-DMT administration for relieving depression and anxiety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Greater acute effects of psychedelics on measures of mystical experiences are associated with positive effects in multiple domains including attitudes, prosocial behavior, depression, anxiety and satisfaction with life in healthy individuals (Davis et al. 2019;Griffiths et al. 2018Griffiths et al. , 2011;;Uthaug et al. 2019).”
From Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study (2023) · cites this paper as Davis et al. 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“it appears that 5-MeO-DMT has an acceptable physiological safety profile in naturalistic settings (Davis et al. 2018; Davis et al. 2019)”
From Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment (2020) · cites this paper as Davis et al. 2019
The cited source says what the claim attributes to it.
In the citing paper
“However, the present findings are in line with previous research on use of synthetic 5-MeO-DMT in ceremonial settings (Davis et al. 2019), as well as a naturalistic observational study investigating the effects following use of toad secretion containing 5-MeO-DMT (Uthaug et al. 2019).”
From Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment (2020) · cites this paper as Davis et al. 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses
Hofmann, S. G., Asnaani, A., Vonk, I. J. J., Sawyer, A. T., & Fang, A. (2012) · Cognitive Therapy and Research · doi:10.1007/s10608-012-9476-1 · Cited by 3,445
The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013
Steel, Z., Marnane, C., Iranpour, C., Chey, T., Jackson, J. W., Patel, V., & Silove, D. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu038 · Cited by 2,846
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 5×
“Three items were also included from the Persisting Effects Questionnaire (24,26,31), in which participants rate the extent to which their first 5-MeO-DMT experience was personally meaningful (on a scale from 0 = “No more than routine, everyday experiences” to 7 = “The single most meaningful experience of my life”), an…”
BackgroundResultInfluentialSelf-citationEpidemiology of anxiety disorders in the 21st century
Bandelow, B., & Michaelis, S. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.3/bbandelow · Cited by 2,079
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citationGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationEpidemiology and treatment of depression in patients with chronic medical illness
J. Katon, W. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/wkaton · Cited by 820
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Self-citationCarbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 596
Self-citationPsilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587
Newby, J. M., McKinnon, A., Kuyken, W., Gilbody, S., & Dalgleish, T. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.06.002 · Cited by 545 · cited 1×
“improvements in self-reported depression and anxiety, which were related to more intense acute mystical effects and increases in ratings of the personal meaning and spiritual significance of the 5-MeO-DMT session, as well as higher ratings of the degree to which the session contributed to improved wellbeing and life s…”
BackgroundPsilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Self-citationCuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., Beekman, A. T., & Reynolds, C. F. (2014) · World Psychiatry · doi:10.1002/wps.20089 · Cited by 424 · cited 1×
“interventions have been developed to address these conditions, which include a combination of psychotherapy and pharmacotherapy (9,10).”
BackgroundMacLean, K. A., Leoutsakos, J. S., Johnson, M. W., & Griffiths, R. R. (2012) · Journal for the Scientific Study of Religion · doi:10.1111/j.1468-5906.2012.01685.x · Cited by 405
Self-citationThe Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review
Sinyor, M., Schaffer, A., & Levitt, A. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500303 · Cited by 396
Birnbaum, H. G., Kessler, R. C., Kelley, D., Ben-Hamadi, R., Joish, V. N., & Greenberg, P. E. (2010) · Depression and Anxiety · doi:10.1002/da.20580 · Cited by 380
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116678781 · Cited by 366 · cited 2×
“tually significant psychedelic experiences (35,41).”
BackgroundSelf-citationThe earth is flat ( p > 0.05): significance thresholds and the crisis of unreplicable research
Amrhein, V., Korner‐Nievergelt, F., & Roth, T. (2017) · PeerJ · doi:10.7717/peerj.3544 · Cited by 331
Potential Therapeutic Effects of Psilocybin
Johnson, M. W., & Griffiths, R. R. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0542-y · Cited by 328
Self-citationGaps in accessing treatment for anxiety and depression: challenges for the delivery of care
Collins, K. A., Westra, H. A., Dozois, D. J. A., & Burns, D. D. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.06.001 · Cited by 322
The hallucinogenic world of tryptamines: an updated review
Araújo, A. M., Carvalho, F. D., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1513-x · Cited by 292
Rubin, M. (2017) · Review of General Psychology · doi:10.1037/gpr0000123 · Cited by 226
Shulgin, A. T., & Shulgin, A. (1997) · Cited by 223
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118769063 · Cited by 140
Self-citationCoull, G., & Morris, P. G. (2011) · Psychological Medicine · doi:10.1017/s0033291711000900 · Cited by 126
Stroud, J., Freeman, T. P., Leech, R., Hindocha, C., Lawn, W., Nutt, D., Curran, H. V., & Carhart-Harris, R. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4754-y · Cited by 110
The Oxford Handbook of Cognitive and Behavioral Therapies
(2015) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780199733255.001.0001 · Cited by 109
Anxiety and depressive symptoms and medical illness among adults with anxiety disorders
Niles, A. N., Dour, H. J., Stanton, A. L., Roy‐Byrne, P., Stein, M. B., Sullivan, G., Sherbourne, C. D., Rose, R. D., & Craske, M. G. (2014) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2014.11.018 · Cited by 105
Ott, J. (2001) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2001.10399925 · Cited by 105
Carhart-Harris, R. L., Williams, T. A., Sessa, B., Tyacke, R. J., Rich, A. S., Feilding, A., & Nutt, D. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110367445 · Cited by 52
Ohlsen, R., Williamson, R. J., Yusufi, B., Mullan, J., Irving, D., Mukherjee, S., Page, E., Aitchison, K. J., & Barnes, T. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091069 · Cited by 42
Data Resource Profile: Countdown to 2015: Maternal, Newborn and Child Survival
Requejo, J. H., Victora, C. G., Bryce, J., & on behalf of the Scientific Review Group of Countdown to 2015 (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu034 · Cited by 26
Treatment of Anxiety Disorders With Comorbid Depression: A Survey of Expert CBT Clinicians
Collimore, K. C., & Rector, N. A. (2014) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2014.01.007 · Cited by 20
(2015) · Journal of Psychopharmacology · doi:10.1177/0269881115622590 · Cited by 1
Research works printed but not linked: 6
- Center for Behavioral Health Statistics and Quality, 2016, National survey on drug use and health: methodological summary and definitions
- 10.1002/wps.v13.1 · DOI
- 10.1177/0269881115622590 · DOI
- 10.1177/0269881115622590 · DOI
- IBM Corp, 2016, IBM SPSS Statistics for Windows, Version 24.0
- 10.1177/0269881115622590 · DOI
Cited by
Sorted by citations
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375
Self-citationCessation and reduction in alcohol consumption and misuse after psychedelic use
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845793 · Cited by 225
Self-citationLong-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.017 · Cited by 279
Self-citationPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05236-w · Cited by 197
Self-citation
Metadata
- Authors
- Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- University of Wyoming (US)
- New School Research, LLC, North Hollywood, CA, USA
- Corresponding author
- Davis, Alan K.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2019-03-01
- Volume
- 45
- Issue
- 2
- Pages
- 161-169
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- PMC
- PMC6430661
- OpenAlex
- W2919995896
- Cited by
- 142
- References
- 43
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 29 · 2023: 21 · 2022: 20 · 2021: 17 · 2020: 13 · 2019: 7
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Drug and Alcohol Abuse (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (AA007747)
- National Institute on Drug Abuse (DA003889, DA007209)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- 5-MeO-DMT, depression, anxiety, psychedelics, mystical experience, challenging experiences, spiritual meaning, group settings, recreational drug use, subjective improvement, hallucinogens
- MeSH terms
- Adult, Depressive Disorder, Female, Hallucinogens, Humans, Male, Methoxydimethyltryptamines, Middle Aged, Psychometrics, Surveys and Questionnaires, Internet, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
